Outcomes based on treatment regimen in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer receiving intravenous or intraperitoneal platinum-based chemotherapy in combination with veliparib and bevacizumab
Gynecologic Oncology(2020)
摘要
Objective: Our goal was to determine whether differences in progression-free survival (PFS) or overall survival (OS) were seen in patients based on regimen of chemotherapy received among epithelial ovarian, peritoneal, or fallopian tube cancer (EOC) patients enrolled on GOG 9923, a phase I study of every-21-day carboplatin/paclitaxel (C/T), weekly C/T, or intravenous and intraperitoneal (IP) paclitaxel/cisplatin in combination with continuous or intermittent/ABT-888 and bevacizumab (BEV) in newly diagnosed previously untreated EOC.
更多查看译文
关键词
fallopian tube cancer,chemotherapy,primary peritoneal,ovarian,platinum-based
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要